LENZ today
$4.11+$0.01 (+0.24%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minExpanding
5 minSymmetric Triangle
Daily trend turns up above $3.71
Key levels
Resistance$4.54
Resistance$4.17
Support$3.71
Support$3.35
Latest news & SEC filings
AnalystCitigroup keeps Buy rating on LENZ Therapeutics, cuts price target
AnalystCitigroup keeps Buy rating on LENZ Therapeutics, cuts price target to $9
All LENZ news →About LENZ Therapeutics
LENZ Therapeutics is a commercial-stage pharmaceutical company that develops and sells medicines aimed at improving eyesight. Its main product is VIZZ, a once-daily aceclidine eye drop approved in the United States for presbyopia, the age-related loss of near vision. The company sells VIZZ in the U.S. through eye care professionals and directly to consumers, and works with partners to commercialize it in parts of Asia, Canada, and the Middle East.
Based on the company's 10-K filed Mar 24, 2026.
Nasdaq · Healthcare
LENZ Therapeutics, Inc. (LENZ)
What Is the Price Target for LENZ?
SEPT Low Target
$10.62
SEPT Mid Target
$12.50
SEPT High Target
$14.37
Analyst Consensus
$12.50
Is LENZ a Buy or Sell Right Now?
Thesis
- •SEC filings signal active product innovation — 2 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for LENZ.
Start Free Trial →Is LENZ Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$13.68
17
Moat Score
NONE
2/9
Piotroski Score
1.7
Altman Z-Score
What Is Smart Money Doing with LENZ?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sale | 2,159,516 | $7.3M | Oct 29, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sale | 451,998 | $1.5M | Oct 29, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sale | 107,170 | $360K | Oct 29, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →LENZ Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-21.79%
FCF Growth YoY
-16.9%
Revenue Trend
UNKNOWN
Dark Pool Trades for LENZ
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for LENZ, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:26:37 | $4.11 | 75,648 | $$311K | SELL |
| 21:00:28 | $4.11 | 1,951 | $$8K | SELL |
| 20:59:50 | $4.10 | 2,000 | $$8K | SELL |
| 20:55:18 | $4.11 | 3,116 | $$13K | SELL |
| 20:55:18 | $4.11 | 1,884 | $$8K | SELL |
5 dark pool trades shown · $$348K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for LENZ Therapeutics, Inc. (LENZ) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →LENZ — frequently asked questions
What is LENZ stock price today?
LENZ Therapeutics, Inc. (LENZ) is at $4.11, up 0.24% (+$0.01) at the Nov 11, 2026 close.
Why is LENZ stock moving today?
Latest LENZ news — Nov 6, 2026: Citigroup keeps Buy rating on LENZ Therapeutics, cuts price target · Nov 5, 2026: Citigroup keeps Buy rating on LENZ Therapeutics, cuts price target to $9
What is the LENZ price target?
The average analyst price target for LENZ is $12.50, ranging from $5 to $20, based on 2 analysts. Latest: Piper Sandler maintains on Oct 19, 2026.
What do analysts rate LENZ?
Analyst ratings for LENZ: 0 Buy, 7 Hold, 1 Sell — consensus Hold.
Did LENZ beat earnings?
LENZ last reported on Oct 29, 2026: EPS -$0.99 vs -$0.89 expected — a miss of 10.8%.
Does LENZ pay a dividend?
LENZ does not currently pay a dividend.
What are LENZ support and resistance levels?
Support: $3.71, $3.35, $2.80. Resistance: $4.17, $4.54, $4.89.
What are insiders doing with LENZ?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on LENZ?
Nov 6, 2026: Citigroup keeps Buy rating on LENZ Therapeutics, cuts price target · Nov 5, 2026: Citigroup keeps Buy rating on LENZ Therapeutics, cuts price target to $9